Lineage Cell Therapeutics advances COR1 corneal cell therapy into in-vivo animal testing

LINEAGE CELL THERAPEUTICS INC

LINEAGE CELL THERAPEUTICS INC

LCTX

0.00
  • Lineage Cell Therapeutics disclosed a preclinical update on COR1, an allogeneic corneal endothelial cell transplant program for corneal endothelial disease.
  • Manufacturing work met internal thresholds for potency, identity, scale; program moved into in-vivo animal testing with initial data expected this year.
  • Management expects a two-tier GMP banking system could support production of millions of final-product doses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.